Gabriel Uwaifo, MD
Endocrinology, Diabetes & Metabolism · Springfield, ILNPI 1043267818
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (49.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Eli Lilly at 36.1% of the total.
Across 71 payments — averaging $154.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$4K
- Corcept Therapeutics$4K
- Bayer$1K
- AstraZeneca$1K
- Lilly USA, LLC$221
- Boehringer Ingelheim$136
- plus $532 from 13 others
Across 38 payments — averaging $4832.18 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$60K
- Amryt Pharma Holdings Ltd$40K
- Boehringer Ingelheim$37K
- Sanofi US Services Inc.$25K
- Boehringer Ingelheim Pharma GmbH & Co.kg$12K
- Takeda Pharmaceuticals U.S.A., Inc.$6K
- plus $5K from 1 others
What the payments were for
- Consulting fees$3,37531%
- Travel & lodging$5,45850%
- Food & beverage$2,14820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 25 | $3,965 |
| Corcept Therapeutics | 6 | $3,696 |
| Bayer | 12 | $1,306 |
| AstraZeneca | 1 | $1,125 |
| Lilly USA, LLC | 7 | $221 |
| Boehringer Ingelheim | 1 | $136 |
| Novo Nordisk | 3 | $90 |
| Sequel Med Tech, LLC | 1 | $90 |
| Dexcom, Inc. | 4 | $80 |
| Mannkind Corporation | 1 | $50 |
| Xeris Pharmaceuticals, Inc. | 2 | $45 |
| Amryt Pharma Holdings Ltd | 1 | $31 |
| Astellas Pharma US Inc | 1 | $25 |
| Radius Health, Inc. | 1 | $23 |
| GRT US Holding, Inc. | 1 | $23 |
| Insulet Corporation | 1 | $22 |
| Nevro Corp. | 1 | $20 |
| Amgen | 1 | $18 |
| Shire North American Group Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,981 in reported general payments places this provider in the 85th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 28 | $47,973 |
| JardianceEmpagliflozin | 25 | $30,141 |
| TrulicityDulaglutide | 14 | $19,953 |
| Testosterone | 19 | $3,010 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $2,698 |
| Repaglinide | 19 | $1,382 |
| SynthroidLevothyroxine Sodium | 11 | $1,074 |
| Levothyroxine Sodium | 66 | $638 |
| Metformin Hcl ErMetformin Hcl | 35 | $339 |
| Atorvastatin Calcium | 18 | $174 |
| Metformin Hcl | 18 | $124 |
| Lisinopril | 18 | $112 |
| Alendronate Sodium | 19 | $107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $90 | $47,97328 claims |
| Boehringer IngelheimJardiance | $136 | $30,14125 claims |
| Lilly USA, LLCTrulicity | $221 | $19,95314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Springfield
- Marina RussoSpringfield$19K
- Wahid KassarChicago$884K
- Anthony PickLake Forest$665K
- Babak PazookiJoliet$582K
- Ammar BayrakdarEvergreen Park$517K
- George BakrisChicago$403K
- Terrence SwadeLombard$369K
- Wenyu HuangChicago$341K
- Liana BillingsSkokie$295K
- Daniel SoArlington Heights$283K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.